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Abstract
Objectives: Parkinson’s disease (PD) patients are more likely to develop impaired nutritional status because of the
symptoms, medications and complications of the disease. However, little is known about the determinants and
consequences of malnutrition in PD. This study aimed to investigate the association of motor, psychiatric and fatigue
features with nutritional status as well as the effects of malnutrition on different aspects of quality of life (QoL) in PD
patients.
Methods: One hundred and fifty patients with idiopathic PD (IPD) were recruited in this study. A demographic checklist, the
Unified Parkinson’s Disease Rating Scale (UPDRS), the Hospital Anxiety and Depression Scale (HADS) and the Fatigue
Severity Scale (FSS) were completed through face-to-face interviews and clinical examinations. The health-related QoL
(HRQoL) was also evaluated by means of the Parkinson’s Disease Questionnaire (PDQ-39). For evaluation of nutritional
status, the Mini Nutritional Assessment (MNA) questionnaire was applied together with anthropometric measurements.
Results: Thirty seven (25.3%) patients were at risk of malnutrition and another 3 (2.1%) were malnourished. The total score
of the UPDRS scale (r =20.613, P,0.001) and PD duration (r =20.284, P= 0.002) had a significant inverse correlation with
the total MNA score. The median score of the Hoehn and Yahr stage was significantly higher in PD patients with abnormal
nutritional status [2.5 vs. 2.0; P,0.001]. More severe anxiety [8.8 vs. 5.9; P= 0.002], depression [9.0 vs. 3.6; P,0.001] and
fatigue [5.4 vs. 4.2; P,0.001] were observed in PD patients with abnormal nutritional status. Except for stigma, all other
domains of the PDQ-39 were significantly correlated with the total score of the MNA.
Conclusion: Our study demonstrates that disease duration, severity of motor and psychiatric symptoms (depression,
anxiety) and fatigue are associated with nutritional status in PD. Different aspects of the HRQoL were affected by patients’
nutritional status especially the emotional well-being and mobility domains.
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Introduction
Nutritional status is an important contributor to quality of life
(QoL) and general condition of daily living in the elderly [1,2]. In
theory, Parkinson’s disease (PD) patients are susceptible to
impaired nutritional status because of different motor and non-
motor symptoms, including psychiatric features and fatigue [3].
Moreover, pharmacological treatment administered in PD can
influence nutritional status through the drugs themselves and their
side effects such as nausea, vomiting and weight loss [4].
Malnutrition can influence immune system, functional status
[5,6], some complications of the disease such as constipation [7]
and potentially increases the likelihood of falling [8]. On the other
hand, dysphagia increases the risk of malnutrition [9] in PD
patients. Despite its important role, nutritional status does not
receive the necessary attention in the management of PD and most
of the time it is ignored.
So far, there have been a number of studies that have evaluated
weight change and/or body mass index (BMI) in PD. However,
only a few of them have focused on general nutritional status using
validated tools such as the Subjective Global Assessment (SGA)
[4,10] and the mini nutritional assessment (MNA) [11,12,13].
Although a few reports used the MNA in PD population, there are
still not enough reports to broadly evaluate the relationship
between different features of the disease and nutritional status, as
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well as its effects on the health-related QoL in PD patients.
Therefore, our study aimed to investigate the association of motor,
psychiatric and fatigue features with nutritional status in PD using
the MNA as a comprehensive instrument. In addition, we also
evaluated the effects of abnormal nutritional status on different
domains of QoL in a population of PD patients.
Subjects and Methods
One hundred and fifty consecutive patients with idiopathic
Parkinson’s disease (IPD) from a single referral Movement
Disorders Clinic in Tehran, Iran, were recruited between October
2011 and December 2012. This was a collaborative project
between the Iran University of Medical Sciences (Tehran, Iran)
and the Karolinska Institutet (Stockholm, Sweden).
Ethics Statement
The ethics committee of the Firoozgar Clinical Research
Development Center (FCRDC) (affiliated with Iran University of
Medical Sciences) approved the study protocol. All of the collected
data were stored and treated according to the ethical guidelines of
medical research. Prior to the launch of the study, all patients were
informed about the aims and procedures. All participants provided
their verbal informed consent to participate in this study. As the
project was designed as an observational research, the verbal form
of consent was approved by the aforementioned ethics committee.
If any patient did not agree to enroll into the study, no extra
evaluation was performed in addition to his/her routine work-up
in the clinic and the research checklist was left blank in the
documentation procedure. Moreover, participation in this study
was voluntary and the patients were free to withdraw from the
project whenever they wanted. Furthermore, the identity of
research participants was protected, since the data files were
anonymous and all of the names were omitted.
Patient Recruitment
Recruited patients fulfilled the United Kingdom Brain Bank
criteria for the diagnosis of IPD [14], which was assessed by the
same neurologist who had specialized in movement disorders for
all of them. All of the IPD patients who were eligible for this study
were required to be 30 years or older with motor disability in the
mild to moderate severity range according to the Hoehn and Yahr
staging criteria [15]. Patients with moderate to severe dementia
[mini-mental state examination (MMSE),24] [16] were excluded
from the study, as were those who were following special diets or
suffering from other diseases considerably influencing nutritional
state. Also, any patient with atypical Parkinsonism, including
multiple system atrophy (MSA), progressive supranuclear palsy
(PSP), and vascular or drug-induced Parkinsonism were not
eligible.
Assessments
Data collection was performed through face-to-face interviews
with the patients and, whenever possible, their caregivers, along
with clinical examinations by means of a checklist and question-
naires. The demographic checklist consisted of baseline variables
(age and sex), educational status, co-morbidities, duration of PD
(time passed from diagnosis) and history of levodopa administra-
tion. These data were collected based on both participants’ self-
reports and their medical records at the referral centre. Clinical
characteristics of PD were assessed using the Unified Parkinson’s
Disease Rating Scale (UPDRS) [17], Hoehn and Yahr stage [15]
and Schwab and England activity of daily living (ADL) scale [18].
The Hospital Anxiety and Depression Scale (HADS) [19]
questionnaire was used to focus on aspects of anxiety and
depression and the Fatigue Severity Scale (FSS) [20] was used
for fatigue measurement. Moreover, the health-related quality of
life (HRQoL) was also evaluated by means of the Parkinson’s
disease quality of life questionnaire (PDQ-39) [21]. In order to
assess the nutritional status, the MNA questionnaire was applied
together with anthropometric measurements.
All of the assessments were done when the patients were in the
‘‘On’’ state. A movement disorder specialist performed all of the
physical examinations and a team of interviewers consisting of
trained medical students and general physicians completed the
interviews to complete the questionnaires.
Scales and Questionnaires
Unified Parkinson’sDiseaseRating Scale (UPDRS). UPDRS
is the most commonly used scale in the clinical study of PD [22], and is
used to assess the severity of PD in different aspects including non-motor
symptoms (part I), activities of daily living (ADL) (part II), motor
examination (part III) and drug complications (part IV). The UPDRS is
scored from a total of 147 points where higher scores reflect worsening
disability [17].
Hoehn and Yahr Stage. The Hoehn and Yahr stage is a
widely used clinical rating scale, supplanted by the UPDRS, which
defines broad categories of motor function in PD. It evaluates the
severity of PD based on functional disability and clinical findings.
It contains five stages, where 0 indicates no visible symptoms of
PD, and 5 shows symptoms on both sides of the body, identifying
those PD patients who are unable to walk. Therefore, a higher
stage shows greater levels of functional disability [15].
Schwab and England Activities of Daily Living (ADL)
scale. The Schwab and England ADL scale is a global scale that
is used for assessing a PD patient’s ability to perform daily
activities in terms of speed and independence through a
percentage figure, where 100% indicates total independence,
and 0% indicates a state of complete dependence, which is seen in
bed-ridden individuals. Therefore, higher scores show greater level
of independence [18].
39-item PD questionnaire (PDQ-39). The PDQ-39 is the
most commonly used instrument for measuring health-related
quality of life in PD patients. It has been developed to assess
treatments and interventions that may benefit PD patients. In its
long format, it contains 39 items assessing eight aspects of QoL in
PD patients: mobility, ADL, emotional well-being, stigma, social
support, cognitions, communication and bodily discomfort. All
questions on the PDQ-39 are coded in a Likert-scale from 0–4,
where 0= never, 1 = occasionally, 2 = sometimes, 3 = often and
4= always. The maximum score of 100 on the PDQ-39 scale
represents the worst condition, with a score of zero representing
the best level of QoL in PD patients [21]. In this study, we used the
Persian-translated version of the PDQ39 questionnaire, which has
been previously shown to have a high reliability with a Cronbach’s
alpha coefficient of 0.93 for the total summary index [23].
Hospital Anxiety and Depression Score (HADS). The
HADS is a screening tool that was designed to assess the levels of
anxiety and depression in a non-psychiatric population attending
medical clinics. It is comprised of 14 questions divided into two
sections; seven questions are related to anxiety and the other seven
focus on depression. Each questionnaire is worth 0–21 points,
providing separate scores for either the anxiety or depression sub-
scales. Responses are determined or calculated by adding up the
sum of 0–3 scores for each question, where 0 = not at all, and 3=
very often indeed [19]. The Cronbach’s alpha coefficient has been
reported as 0.78 for anxiety and 0.86 for the depression sub-scale
Nutritional Status in Parkinson’s Disease
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of the Persian-version of the HADS questionnaire [24] used in our
study.
Fatigue Severity Scale (FSS). The FSS is an instrument that
assesses the physical aspects of fatigue and their impact on the
patient’s daily function in a variety of medical and neurologic
disorders. It evaluates the impact of fatigue on motivation,
exercise, physical functioning, and carrying out duties and
responsibilities, as well as interfering with work, family, or social
life. It contains nine questions, with a maximum score of 36 points.
We asked each patient to rate the level of fatigue during the past
week with scores from 1 to 7 for each statement. Lower values
indicate strong disagreement with the statement, whereas higher
values indicate strong agreement [20]. A total score is obtained as
the average of all of the item-specific scores where higher scores
correspond with more severe fatigue. The FSS questionnaire was
previously translated into the Persian language and showed
acceptable validity and reliability [25]. In this project, we used
this Persian-translated version of the FSS questionnaire in our
sample of IPD patients.
Mini Nutritional Assessment (MNA). The MNA is a rapid
nutrition-assessment tool that can be used for the elderly in order
to identify the risk of malnutrition. Moreover, its usefulness
extends as a comprehensive geriatric assessment tool that can help
in identifying patients who may benefit from early intervention
[26]. It has also been seen as a combined screening and assessment
tool [27]. The MNA questionnaire consists of brief questions and
simple measurements that can be completed in about 10–15
minutes [26]. The full format of the MNA includes 18 items
grouped into two sub-sections: six screening questions in the first
section and 12 assessment questions in the second section. The
MNA scale includes body mass index (BMI), weight loss, arm and
calf circumference, appetite, medication, general and cognitive
health, dietary matters, autonomy of feeding, and self-perception
of health and nutrition, as well as a subjective judgment of
malnutrition. The maximum score in the MNA questionnaire is 30
points, where 16 points are obtained by screening questions and
14 points are gained through assessment questions. A total score of
less than 17 points indicates ‘‘malnutrition’’, scores of 17–23.5 points
signify cases that are ‘‘at risk for malnutrition’’, while scores equal to
or more than 24 points represent ‘‘normal nutritional status’’ [28]. In
this study, we have used the full format of the Persian-translated
MNA provided by the Nestle´ Nutrition Institutet [29] and the total
score is reported. Moreover, according to the small sample size in
subgroup comparisons, all of the patients with a total MNA score
of,24 are mentioned as ‘‘abnormal nutritional status’’, including both
malnourished and at-risk patients.
Anthropometric Measurements. As a part of the MNA
questionnaire, each participant underwent anthropometric mea-
surements including mid arm circumference (MAC), calf circum-
ference (CC), weight and height. Body weight was recorded in a
standardised manner using calibrated floor scales while the
subjects wore light clothing with no shoes or coats. For all
patients, the weight measurement was performed between 3 p.m.
and 5 p.m. when they were supposed to have left at least 2 hours
since their lunch and had not yet had their dinner. The standing
height was measured using a stadiometer at head level, with the
subject’s bare feet close together, standing erect and looking
straight ahead. Of note, there was no case of considerable stooped
posture for any height adjustment. Body mass index was calculated
as body weight (kg) divided by the square value of height (m2). For
the MAC, the examiner marked the mid-point between the
acromial surface of the scapula (bony protrusion surface of upper
shoulder) and the olecranon process of the elbow (bony point of
the elbow) on the back of the arm, while the subject was asked to
hold the forearm in a horizontal position with their palm up.
Thereafter, the MAC was measured with a flexible inextensible
tape that was applied snugly around the maximum girth of the
proximal part of forearm while the subject’s arm was hanging
down freely along their trunk at their sides. For the CC, the
maximal circumference between the ankle and the knee was
measured with a flexible tape that was applied horizontally around
the maximum girth of the calf, while the subject was standing with
their weight evenly distributed on both feet [30]. In order to
accurately measure the MAC and CC, we asked the participants
to roll up their trouser leg or sleeve to uncover their calf or arm,
respectively.
Statistical Analysis
All of the data obtained from the checklists and questionnaires
were entered into SPSS software version 20 (IBM; Chicago, IL,
USA). Numerical variables are described using the mean and
standard deviation (SD), whereas, the discrete values of the Hoehn
and Yahr stage are presented as the median and interquartile
range (IQR). The relative frequency percentage is also used to
describe the nominal or categorical variables. The Kolmogorov-
Smirnov (K-S) test was used to check the normality of the
distribution of the total MNA score, which was shown to be
skewed and non-normal (K-S test P=0.003). The univariate
relationship between the total MNA score and those obtained
from other scales and questionnaires was assessed by means of the
Spearman correlation test. In subgroup analysis, the independent
samples T test was performed to compare the mean scores of
different questionnaires between the IPD patients with normal
versus abnormal nutritional status. Moreover, the Mann-Whitney
U test was used to compare the mean of the total MNA score
between female and male patients. It must be noted that according
to the rather small sample size in subgroup comparisons, the two
subgroups of patients with ‘‘malnutrition’’ and ‘‘at risk of malnutrition’’
were merged together in one group called ‘‘abnormal nutritional
status’’.
Further multivariate analysis was performed using a stepwise
linear regression model in order to evaluate the factors indepen-
dently related to the total score of the MNA questionnaire among
IPD patients. In addition, binary logistic regression analysis was
performed using a forward conditional model to identify the
factors that could independently discriminate the IPD patients
with abnormal nutritional status. In both regression models, age at
the time of diagnosis, sex, weight-adjusted daily levodopa dosage,
the score of each part of the UPDRS scale, total UPDRS score,
Hoehn and Yahr stage, Schwab and England ADL score, anxiety,
depression and fatigue scores were defined as the predictor list. A
two-tailed P-value of less than 0.05 was considered to show a
statistically significant difference or correlation in all analytical
procedures.
Results
Baseline and Anthropometric Characteristics
In total, 150 PD patients were recruited into this study
consisting of 103 (68.7%) males and 47 (31.3%) females with a
mean age of 60.8 (SD=10.8) yrs, ranging between 32 and 84
years, and a mean disease duration of 6.8 (SD=5.3) yrs. Table 1
summarises information on the baseline, anthropometric and
clinical characteristics of the recruited PD patients. The mean of
the total UPDRS score was 31.7 (SD=17.2) ranging from 6 to 88.
The median score of Hoehn and Yahr staging was 2.0 (IQR=1.5)
and the mean percentage of the Schwab and England ADL scale
was 81.7% (SD=16.7).
Nutritional Status in Parkinson’s Disease
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Table 2 shows the descriptive results for nutritional status
(MNA), disease-related quality of life (PDQ-39), and severity of
anxiety, depression (HADS) and fatigue (FSS) in PD patients. The
highest scores (worst conditions) of PDQ-39 were observed in
emotional well-being [27.7 (SD=22.7)] and mobility [26.8
(SD=25.1)] domains. The mean of the total MNA score was
25.1 (SD=3.3) and regarding the cut-off points, 37 (25.3%) PD
patients were at risk of malnutrition and another 3 (2.1%) cases
were already malnourished.
Univariate Correlations with the MNA Score
Table 3 summarises the univariate correlation coefficients
between the scores of different motor, psychiatric, fatigue and
quality of life (PDQ-39) scales and nutritional status (MNA).
Except for stigma, all other domains of PDQ-39 were significantly
and inversely correlated with the total score of the MNA
questionnaire (all P,0.05). The mobility domain of the disease-
related QoL had the largest inverse correlation with the total
MNA score (Spearman r=20.590, P,0.001), and the emotional
well-being domain was the second most important related factor to
the total MNA score (Spearman r=20.461, P,0.001) in the
population of recruited PD patients.
As listed in Table 3, all sections of the UPDRS scale of disease
severity had a significant inverse correlation with the total score of
the MNA including the mental (Spearman r=20.503, P,0.001),
ADL (Spearman r=20.518, P,0.001), motor (Spearman r=2
0.473, P,0.001) and complication (Spearman r=20.336, P,
0.001) parts as well as the total UPDRS score (Spearman r=2
0.613, P,0.001). Also, the more severe motor symptoms (Hoehn
and Yahr: Spearman r=20.414, P,0.001) and morbidity
(Schwab and England: Spearman r= 0.492, P,0.001) observed,
the lower the total MNA scores recorded among the recruited PD
patients. All of the evaluated non-motor symptoms were signifi-
cantly correlated with the MNA scores (all P,0.01). However, the
Table 1. Baseline, anthropometric and clinical characteristics of the recruited Parkinson’s disease patients (n = 150).
Characteristics Value
Age (yr)-Mean (SD) 60.8 (10.8)
Gender NO.(%)
Female 47 (31.3)
Male 103 (68.7)
Level of Education NO.(%)
Illiterate 15 (10.1)
Primary and/or Secondary 36 (24.3)
High School/Diploma 41 (27.8)
College and/or University 56 (37.8)
Duration of Disease (yr)-Mean (SD) 6.8 (5.3)
Co-morbidities NO.(%)
Depression 36 (24.5)
Hypertension 24 (16.2)
Cardiovascular Disease 23 (15.8)
Osteoarthritis 19 (13.0)
Diabetes 18 (12.3)
UPDRS Score-Mean (SD)
Part I-mental 2.1 (2.3)
Part II-ADL 11.2 (6.9)
Part III-motor 15.3 (8.8)
Part IV-complications 3.5 (2.8)
Total 31.7 (17.2)
Hoehn & Yahr Stage-Median (IQR) 2.0 (1.5)
Schwab and England Activities of Daily Living Score (%)-Mean (SD) 81.7 (16.7)
Daily levodopa dose-Mean (SD)
Crude (mg) 812 (490)
Weight-adjusted (mg/kg) 11.75 (7.72)
Anthropometric Measurements-Mean (SD)
Weight (kg) 71.8 (13.6)
Height (cm) 166.7 (8.8)
Body Mass Index (BMI) (kg/m2) 25.8 (4.2)
Mid-Arm Circumference (MAC) (cm) 28.2 (4.9)
Calf Circumference (CC) (cm) 34.9 (3.8)
doi:10.1371/journal.pone.0091153.t001
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HADS score of depression was the strongest one associated with
the total score of the MNA questionnaire (Spearman r=20.577,
P,0.001). Moreover, both anxiety (Spearman r=20.369, P,
0.001) and fatigue (Spearman r=20.413, P,0.001) scores were
inversely correlated with the total MNA score. The probable
associations of two other continuous variables, age and disease
duration, with the MNA score were also assessed. Interestingly,
total MNA score was significantly inversely correlated with disease
duration (Spearman r=20.284, P=0.001) in the absence of such
an association with patients’ age (P=0.271). In addition, while no
correlation was found between the cumulative daily dosage of
levodopa and total MNA score (Spearman r=20.085, P=0.310),
the weight-adjusted levodopa dose was inversely correlated with
total MNA score (Spearman r=20.218, P=0.009). The result of
the Mann-Whitney U test demonstrated that the mean of the total
MNA score was significantly lower among the female PD patients
compared to the male cases [23.7 (SD=4.3) vs. 25.8 (SD=2.6);
P=0.002].
Univariate Comparisons between Patients with Normal
versus Abnormal Nutritional Status
As shown in Table 4, the patients with abnormal nutritional
status had a significantly longer history of PD compared to those
with normal nutritional status [8.2 (SD=6.9) yrs vs. 6.2 (SD=4.6)
yrs; t-value =22.02, P=0.045]. The results of the independent
samples T test confirmed that except for stigma, the mean score of
other domains of the PDQ-39 questionnaire was significantly
different between PD patients with different nutritional status (all
P,0.05). In addition to each part of the UPDRS scale, the mean
of the total UPDRS score was significantly higher among the PD
patients with abnormal nutritional status [45.9 (SD=18.0) vs. 26.4
(SD=13.6); t-value =26.50, P,0.001]. Accordingly, the median
score of the Hoehn and Yahr staging was significantly higher in
PD patients at risk of malnutrition compared to those with normal
nutritional status [2.5 (IQR=1.0) vs. 2.0 (IQR=1.5); t-value =2
4.55, P,0.001]. Based on the Schwab and England ADL score,
the PD patients with abnormal nutritional status were also more
disabled compared to the subgroup with normal nutrition [71.2
(SD=19.6) vs. 85.7 (SD=13.9); t-value = 4.29, P,0.001]. In
addition, more severe anxiety [8.8 (SD=5.2) vs. 5.9 (SD=4.9);
t-value =23.08, P=0.002], depression [9.0 (SD=4.2) vs. 3.6
(SD=3.5); t-value =27.77, P,0.001] and fatigue [5.4 (SD=1.5)
vs. 4.2 (SD=2.0); t-value =24.00, P,0.001] were found in PD
patients with abnormal nutritional status.
Multivariate Analysis
The continuous score of the whole MNA scale was assigned as
the outcome of interest in a forward (stepwise) multivariate linear
model where the entire regression was statistically significant
(R2 = 0.539, P,0.001, Table 5- model 1). Of interest, with regard
to independent variables that remained significant in the
regression model, depression (regression coefficient =20.352,
P,0.001), total score of the UPDRS scale (regression coeffi-
cient =20.313, P,0.001), weight-adjusted daily levodopa dosage
(regression coefficient =20.190, P=0.006) and patients’ sex
(regression coefficient =20.196, P=0.003) were found to be
significantly associated with the total MNA score.
The logistic regression model was also statistically significant
(R2 = 0.496, P,0.001, Table 5- model 2). The forward conditional
model revealed that the Hoehn and Yahr stage [OR=2.4 (95%
CI: 1.3–4.5); P=0.007] and depression score [OR=1.4 (95% CI:
1.2–1.6); P,0.001] independently discriminated the PD patients
suffering from malnutrition.
Discussion
In this study, we used MNA to assess nutritional status in a
group of PD patients with the mean age of 61 (SD=10) yrs, which
is close to the age range of the previous report by Wang et al. [65
(SD=9) yr] who used MNA in the PD population [11]. Although
the age distribution of our participants was skewed through the
inclusion of elderly individuals, it ranged between 32 and 84 yr. As
an assessment tool, MNA has shown reliable and valid results to
screen those elderly patients at risk of malnutrition [31]; however,
there are some reports that reveal reproducible results of using
MNA in younger adults aged .18 years [32] or in those with a
mean age of around 41 yrs [33], though both studies were
conducted in patients with chronic kidney disease. Specifically in
Table 2. Descriptive characteristics of nutritional status (MNA), disease-related quality of life (PDQ-39), anxiety, depression (HADS)
and fatigue (FSS) in Parkinson’s disease (PD) patients.
Questionnaire/Domain Mean (SD) Range
MNA (Total) 25.1 (3.3) 6–30
PDQ-39 domains
Mobility 26.8 (25.1) 0–100
Activities of daily living (ADL) 23.4 (22.9) 0–100
Emotional well-being 27.7 (22.7) 0–100
Stigma 21.6 (25.1) 0–100
Social support 7.1 (13.3) 0–75
Cognitive impairment (Cognition) 16.6 (18.3) 0–81
Communication 14.2 (17.9) 0–83
Bodily discomfort 20.9 (20.8) 0–75
HADS domains
Anxiety 6.8 (5.1) 0–20
Depression 5.1 (4.5) 0–17
FSS 4.5 (1.9) 1–7
doi:10.1371/journal.pone.0091153.t002
Nutritional Status in Parkinson’s Disease
PLOS ONE | www.plosone.org 5 March 2014 | Volume 9 | Issue 3 | e91153
the case of the PD population, Sheard et al. showed the superior
validity of the short form of the MNA compared to other screening
tools such as BMI and weight changes. Nevertheless, the Patient-
Generated Subjective Global Assessment (PG-SGA) demonstrated
better results compared to the full MNA questionnaire for
nutritional assessment in a group of PD patients who are aged
between 35 and 92 yrs [34].
In our study population, malnutrition was found in 2% of the
PD patients, while almost a quarter of them were at risk of
malnutrition. This figure is close to the reports from the studies by
Wang et al. [11] and Barichella et al. [12], illustrating 20% and
22.9% of the risk of malnutrition in Chinese and Italian PD
populations, respectively. The rate of malnutrition was also
estimated to be as low as 1.7% by Wang et al., which was
contributed to race, age, Hoehn and Yahr stage, source of
participants’ recruitment (from outpatient clinics) and disease
duration [11]. On the other hand, there are some other reports
showing more prevalent malnutrition in PD populations to as high
as 15.6% [35], 19.5% [36] and 23.6% [37] using BMI measures.
Our findings demonstrate that many motor, psychiatric and
fatigue symptoms are significantly associated with nutritional
status in PD patients. PD patients with abnormal nutritional status
Table 3. Pearson correlation between the scores of different motor, psychiatric, fatigue and quality of life (PDQ-39) scales and
nutritional status (MNA) in Parkinson’s disease (PD) patients.
Scale Domains Correlation Index MNA (Total)
PDQ39 Mobility Spearman R 2.590**
P-value ,.001
Activities of daily living (ADL) Spearman R 2.450**
P-value ,.001
Emotional well-being Spearman R 2.461**
P-value ,.001
Stigma Spearman R 2.027
P-value .744
Social support Spearman R 2.246**
P-value .005
Cognitive impairment (Cognition) Spearman R 2.320**
P-value ,.001
Communication Spearman R 2.414**
P-value ,.001
Bodily discomfort Spearman R 2.451**
P-value ,.001
Disease Severity UPDRS Part I-mental Spearman R 2.503**
P-value ,.001
UPDRS Part II-ADL Spearman R 2.518**
P-value ,.001
UPDRS Part III-motor Spearman R 2.473**
P-value ,.001
UPDRS Part IV-complications Spearman R 2.336**
P-value ,.001
UPDRS Total Spearman R 2.613**
P-value ,.001
Hoehn & Yahr stage Spearman R 2.414**
P-value ,.001
Schwab & England stage Spearman R .492**
P-value ,.001
HADS Anxiety Spearman R 2.369**
P-value ,.001
Depression Spearman R 2.577**
P-value ,.001
FSS Fatigue Spearman R 2.413**
P-value ,.001
**Correlation is significant at the 0.01 level (2-tailed).
*Correlation is significant at the 0.05 level (2-tailed).
doi:10.1371/journal.pone.0091153.t003
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(including malnourished and at risk of malnutrition) had more
severe symptoms in all parts of the UPDRS scale including motor,
non-motor, ADL and complications. Both dyskinesia and the
wearing-off phenomenon were more common among PD patients
with abnormal nutritional status in whom the Hoehn and Yahr
stage and the Schwab and England ADL scores also showed more
severe disease. Among the evaluated psychiatric features, more
severe depression, anxiety and fatigue were reported in PD
patients with nutritional problems. Besides PD symptoms, health-
related QoL was also affected by nutritional status. As our findings
show, except for stigma, in all other domains of the PDQ-39, the
PD patients with abnormal nutritional status showed worse QoL-
scores. In other words, poor nutritional status was accompanied
with poor QoL in a group of patients with chronic conditions such
as PD. It is noteworthy that different domains of QoL such as
disability-related features, cognition, communication, and emo-
tional and social aspects were all correlated with the MNA score in
the PD population. To our knowledge, this study is one of the few
that directly assess the relationship between nutritional status and
HRQoL by means of MNA and PDQ-39 tools in the PD
population. However, using MNA in another elderly population,
malnourished subjects or those at risk of malnutrition have been
shown to have poorer QoL and function in rehabilitation centres
[2].
Based on multivariate regression analysis, female gender, higher
weight-adjusted daily levodopa dosage, more severe disability
(higher UPDRS score, more advanced Hoehn and Yahr stage) and
more severe depression predicted a lower MNA score or a higher
risk of nutritional deficiency in the PD population, when
univariate-independent relationships were adjusted for other
covariates. These factors represent the role of demographic (sex),
disease severity (UPDRS, Hoehn and Yahr stage), psychiatric
(depression) and pharmaceutical (weight-adjusted daily levodopa
dosage) features of PD in association with nutritional status. We
found significantly lower MNA scores among the female PD
population, which is in line with the previously published reports
indicating female gender as a risk factor for malnutrition in the
elderly based on the total MNA score [38]. With regard to the
Hoehn and Yahr stage as a measure of PD severity, the current
literature is controversial. Two previous reports have shown no
significant difference in the Hoehn and Yahr stage when
comparing poor nutritional status with the well-nourished PD
patients [11,39]. In contrast to these previous reports and similar
to our current study, Markus et al. [37], Beyer et al. [40], Uc et al.
[35] and Sheard et al. [41] reported a statistically significant
correlation between Hoehn and Yahr stage and either BMI, the
amount of weight change or nutritional status in a PD population.
Table 4. Comparison of the mean [standard deviation (SD)] scores of different motor, psychiatric, fatigue and quality of life (PDQ-
39) scales between subgroups of Parkinson’s disease (PD) patients regarding nutritional status (MNA).
Scale Domain
Abnormal nutritional status
(n = 40)
Normal nutritional status
(n = 106) t-value P-value
Baseline Age (yr) 61.3 (12.3) 61.3 (9.8) 20.02 .982
Disease duration (yr) 8.2 (6.9) 6.2 (4.6) 22.02 .045*
Body mass index (BMI) (kg/m2) 23.9 (3.8) 26.6 (4.3) 3.57 .001*
Daily levodopa dose
Crude (mg) 817 (450) 841 (490) 0.27 .789
Weight-adjusted (mg/kg) 13.55 (8.92) 11.50 (6.94) 21.46 .146
PDQ39 Mobility 45.6 (26.6) 19.4 (20.7) 25.61 ,.001*
Activities of daily living (ADL) 38.4 (28.9) 18.0 (17.9) 23.97 ,.001*
Emotional well-being 41.3 (22.4) 22.1 (20.8) 24.90 ,.001*
Stigma 22.0 (24.4) 21.5 (25.4) 20.11 .913
Social support 13.0 (17.2) 5.1 (10.9) 22.51 .016*
Cognitive impairment 25.5 (20.5) 13.5 (16.6) 23.64 ,.001*
Communication 24.6 (23.9) 10.3 (13.6) 23.56 .001*
Bodily discomfort 32.5 (20.3) 16.4 (19.6) 24.30 ,.001*
Disease
Severity
UPDRS: Part I-mental 3.8 (3.2) 1.3 (1.4) 24.69 ,.001*
UPDRS: Part II-ADL 15.9 (7.8) 9.4 (5.8) 25.17 ,.001*
UPDRS: Part III-motor 20.6 (10.1) 13.3 (7.4) 24.18 ,.001*
UPDRS: Part IV-complications 5.1 (3.4) 2.9 (2.2) 23.80 ,.001*
a. Dyskinesia 1.7 (2.5) .8 (1.4) 22.08 .042*
b. Wearing off 2.3 (1.4) 1.5 (1.2) 23.06 .003*
UPDRS: Total 45.9 (18.0) 26.4 (13.6) 26.50 ,.001*
Hoehn & Yahr stage # 2.5 (1.0) 2.0 (1.5) 24.55 ,.001*
Schwab & England stage (%) 71.2 (19.6) 85.7 (13.9) 4.29 ,.001*
HADS Anxiety 8.8 (5.2) 5.9 (4.9) 23.08 .002*
Depression 9.0 (4.2) 3.6 (3.5) 27.77 ,.001*
FSS Fatigue 5.4 (1.5) 4.2 (2.0) 24.00 ,.001*
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Regarding psychiatric symptoms and fatigue, there are few
similar studies to directly evaluate the relationship between these
symptoms and nutritional status in PD. Our findings are in line
with previous reports, which show that neuropsychiatric symptoms
such as depression, anxiety, dementia, confusion, and apathy
contribute to decreased food intake and subsequent weight loss in
an elderly PD population [35,42,43]. In line with the results of our
study, both Wang et al. [11] and Sheard et al. [41] reported
depression as a significant predictor of nutritional status in PD
patients. Wang et al. [11] considered many non-motor symptoms
in their study and showed that both depression and anxiety were
associated with a risk of malnutrition in PD. More recently, a
higher depression score was shown in malnourished PD patients
by using the Beck’s depression inventory (BDI) [41]. Our study
uniquely considered fatigue as another factor that might interact
with the negative association of depression and anxiety with
nutritional status in PD patients. We showed that in addition to
previously evaluated psychiatric symptoms, fatigue significantly
correlated with malnutrition in PD. Having assessed nutritional
status by MNA in another elderly population, Bollwein et al.
underlined the close association between frailty syndrome (includ-
ing exhaustion, low physical activity and slow walking speed) and
nutritional status [44]. However, fatigue and exhaustion seem to
be both the cause and consequence of malnutrition in the elderly.
Emotional well-being, depression and fatigue are important
determinants in health status as they are directly associated with
the general condition in PD. Additionally, PD can lead to a
reduction in mobility, hindering older persons from performing
daily activities, such as shopping or food preparation [45].
Our study confirms that more severe motor symptoms and
more common dyskinesia are found among PD patients with
abnormal nutritional status, which is in line with a similar study
performed by Sheard et al. [41]. Although using another scale
(SGA) to evaluate nutritional status in a PD population, they also
observed higher UPDRS scores among the malnourished partic-
ipants [41]. The association between malnutrition and disease
severity may be due to eating and digesting difficulties occurring in
PD [46]. Hypothetically, people with better nutritional status, as
indicated by a higher MNA score, may demonstrate a more
nutritious dietary pattern when younger, having maintained their
healthy diet into late-adulthood. This would increase their odds of
being in the groups with higher MNA scores. However, it is not
possible to determine the temporality between nutritional status
and PD severity by a cross-sectional designed study.
In the present study, BMI was also closely correlated with the
nutritional status assessed by MNA. An average of a three-unit
lower BMI was observed in PD patients at risk of malnutrition in
our study. This finding is in line with a previous report that shows
an even lower BMI among the moderately malnourished PD cases
compared to the well-nourished patients (20.0 kg/m2 vs. 25.9 kg/
m2) [10]. In parallel, it has been previously shown that different
doses of levodopa administered as the main PD treatment may
affect BMI levels [46]. In contrast, no association was detected by
Nozaki et al. between PD treatment and weight loss [47]. This can
be seen in other studies where no correlation was found between
levodopa dose, duration, and weight changes [48]. Similarly, we
did not find any relationship between the daily dosage of levodopa
and nutritional status, and Sheard et al. also reported this lack of
association [41]. However, they found a relationship between the
weight-adjusted dose of levodopa (mg per kg body weight) and
MNA score [41]. Of interest, we also observed an inverse
correlation between the weight-adjusted daily dosage of levodopa
and total MNA score, which demonstrates a higher adjusted dose
in PD patients with worse nutritional status (lower MNA score).
This finding is consistent with the report by Barichella et al. who
recently confirmed that nutritional risk depends on weight-
adjusted levodopa dose in PD outpatients [49]. These findings
highlight an intrinsic association between nutritional status and
both the course of disease and levodopa-related complication in
PD patients [49,50,51].
Most interestingly, an inverse relationship was also found
between MNA score and disease duration. While a lower MNA
Table 5. Multivariate regression models to determine the motor and non-motor factors independently related to total score of the
MNA questionnaire (model 1) and having abnormal versus normal nutritional status (model 2) in recruited Parkinson’s disease (PD)
patients.
Model 1: Linear regression (Dependent variable: total MNA score)
Significant Variables Unstandardized Coefficients Standardized Coefficients t P-value
B SEM Beta
Depression score 2.292 .064 2.352 24.547 ,.001
Total score of UPDRS 2.064 .016 2.313 23.903 ,.001
Gender 21.525 .503 2.196 23.032 .003
Weight-adjusted levodopa dosage 2.085 .030 2.190 22.815 .006
Constant 30.153 .504 – 59.868 ,.001
Model 2: Binary Logistic regression (Dependent variable: abnormal vs. normal nutritional status)
Significant Variables B SEM OR (95% CI) Wald P-value
Hoehn & Yahr stage .865 .322 2.38 (1.26–4.46) 7.232 .007
Depression score .354 .072 1.42 (1.24–1.64) 24.262 ,.001
Constant 24.984 .971 – 26.330 ,.001
In both regression models, age at the time of diagnosis, sex, weight-adjusted levodopa dosage, the score of the each part of the UPDRS scale, total UPDRS score, Hoehn
& Yahr stage, Schwab & England ADL score, anxiety, depression and fatigue scores were entered as the predictor list.
doi:10.1371/journal.pone.0091153.t005
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score was accompanied by longer disease duration in PD patients,
no association was found between the MNA score and patient’s
age. Previously published evidence shows conflicting results on this
issue. While no difference in nutritional status, assessed by MNA,
was found regarding PD duration in one study [11], Barichella
et al. demonstrated a linear correlation between the MNA score
and the duration of PD, even though no correlation was observed
between MNA and the chronological age of the patients [12].
These patterns are quite consistent with our findings in the Iranian
PD population, which showed an independent association between
MNA and PD duration.
Our study suffers from some limitations, which must be taken
into account when generalising its findings. One issue refers to
the fact that no serum measurement was performed to quantify
blood indicators of nutrition. Similar to most previous reports
on this issue, the primary focus is on BMI and weight loss,
whereas other indicators of nutritional condition such as food
intake, fat and muscle status are not considered in our study.
However, as an innovative clinical evaluation instrument, the
MNA questionnaire provides several questions and four
anthropometric measurements without any need for blood
sampling or other clinical measurements. MNA is an acceptable
tool to assess nutritional status especially among those elderly
who are aged .65 yrs; therefore, our findings regarding younger
patients might not be as valid as those of older ones.
Nevertheless, this is the real-life condition of PD population in
referral movement disorder centres, and other reports with
rather similar ranges of age also used this tool and showed its
validity in PD [11,34]. Our study has primarily been designed
as a cross-sectional study, which did not allow for the
determination of directionality of the association or the so-
called causality between malnutrition and PD-related factors.
Similar to previous studies, it is not clear whether poor
nutritional status is ‘‘the chicken or the egg’’, i.e. the cause or
the effect [52]. In a cross-sectional study, such as ours, the
relationship between PD symptoms and nutritional status can be
reciprocal. While poor symptom control can increase the risk of
poor nutritional status, malnutrition can also result in poor
symptom control. Moreover, the recruited patients in our study
were PD outpatients who attended a referral movement disorder
clinic. This selection bias has restricted our samples to the
group of mild-to-moderate stage non-hospitalised PD patients.
The more severe or end-stage cases, which are potentially at a
higher risk of malnutrition, were not able to participate in this
study. In order to have more valid data, patients with moderate
to severe dementia were also excluded. However, as dementia is
a known risk factor of poor nutritional status, this exclusion
criterion can also further restrict the generalisability of our
findings. As a result, our findings are better to be generalised
into an outpatient PD population with mild-to-moderate stages
of the disease who are not suffering from severe dementia.
Finally, as has been observed in other clinical recordings, some
parts of the information were self-reported and based on
interviews with the patients and/or their caregivers, hence liable
to inaccuracies. Recall bias may have also occurred, causing
over- or under-estimated reports for some of the answers.
Besides the limitations, our study is the first investigation to
contribute to a better understanding of the nutritional status
among Iranian PD patients. This study benefits from a large
sample size, leading to an acceptable statistical power, as well as
a comprehensive list of motor and psychiatric symptoms and the
HRQoL, which makes the findings reliable and precise. In
addition, we used the MNA questionnaire as an accepted tool
to assess nutritional status, while many of the previous studies
commonly used BMI and/or body weight instead.
In conclusion, evaluation of nutritional status using the MNA
questionnaire in this population of PD patients has demonstrated
that there is a significant correlation between PD duration and
nutritional status. This significant correlation without considering
chronological age, reduces the possibility that the worse MNA
scores in patients with longer PD duration were due only to
increasing age. In addition, we indicated that PD-related factors
are associated with malnutrition in these patients. Many non-
motor psychological aspects of PD were related to nutritional
status as well as disease severity and level of morbidity. Different
aspects of the HRQoL were also closely associated with patients’
nutritional status. These cross-sectional data raise further questions
and hypotheses regarding whether the individuals with insufficient
nutrient intake in the past are more likely to experience
malnutrition and a more severe course of PD, or if the presence
of PD symptoms can hinder the capability or willingness to engage
in appropriate nutritious meal preparation.
The significant correlations between the non-motor and motor
symptoms of PD with malnutrition and its association with QoL
bring to light the idea of using a tool to assess nutritional status in
the routine evaluation of PD as the disease progresses. MNA
appears to be a practical, user-friendly and cheap assessment tool
for this purpose. Although the role of nutrition in the progression
of neurodegenerative disorders still needs more clarification,
theoretically, a vicious circle can be created if nutritional features
of PD are ignored that can themselves worsen their QoL.
Nevertheless, conducting follow-up longitudinal assessments and
further studies involving PD patients with more severe stages of the
disease may help in providing a more comprehensive picture of the
nutritional status and the inter-relationships with motor and
psychiatric symptoms and fatigue in PD patients.
Overall, nutritional screening using instruments such as MNA
is an easy and quick way to identify patients with PD who may
be at risk of malnutrition. They can then be assessed to
determine if they are malnourished and to determine appropri-
ate interventions. Based on our findings, PD patients with more
depressive symptoms, severe fatigue and more severe disability
who are under higher weight-adjusted levodopa dose are more
likely to suffer from poor nutritional status and may benefit
more from nutritional screening and follow-up assessment.
Regardless of the direction of this relationship, including dietary
education in the care approaches used for PD patients seems to
improve their QoL.
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